Real-world efficacy, safety, and usability of a microvolume eyedrop delivery device in glaucoma: prospective randomized crossover trial
MD delivered with the Nanodropper adaptor provided additional IOP-L, significantly reduced PBE, and decreased the occurrence and severity of nonsystemic AEs compared with CD in this cohort of stable primary open-angle glaucoma/ocular hypertension participants. MD use among glaucoma participants may enhance tolerability, and improve adherence and long-term IOP control.
Authors
- Elizabeth Colantuoni (ORCID: https://orcid.org/0000-0002-0091-9434)
- Allisa J. Song (ORCID: https://orcid.org/0000-0001-7024-9061)
- Jared C. Kelstrom
- Alan L. Robin (ORCID: https://orcid.org/0000-0003-1959-8770)
- Alexandra J Schulte
- Alexandra Papp
- Jennifer S. Steger (ORCID: https://orcid.org/0000-0002-4356-6739)
- José E. Capó‐Aponte
- Eric P. Grewal
Institutions
- Mayo Clinic (US)
- Johns Hopkins University (US)
- Uniformed Services University of the Health Sciences (US)
- University of Michigan (US)
- Wilford Hall Ambulatory Surgical Center (US)
- David Grant USAF Medical Center (US)
- Southern California Eye Institute (US)
- University of Minnesota Rochester (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Journal of Cataract & Refractive Surgery
- Published
- 2025-11-04
- DOI
- https://doi.org/10.1097/j.jcrs.0000000000001823
- Primary Topic
- Glaucoma and retinal disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00